Most powerful obesity drug yet: People lost up to 25% of weight in trial
摘要
最新肥胖药物retatrutide的后期临床试验数据显示，肥胖患者使用最高剂量80周后平均减重25%，延长至104周后平均减重30%，超过三分之一参与者减重达30%及以上。该药还改善了膝骨关节炎患者的膝关节疼痛、阻塞性睡眠呼吸暂停患者的事件次数，以及血压、甘油三酯和低密度脂蛋白胆固醇等心血管代谢指标。试验始于2023年，涵盖11个国家131个试验点的2339
Researchers published late-stage clinical trial data today for the latest obesity drug, retatrutide—expected to be the most powerful formula yet—and the results appear in line with high expectations. Patients with obesity on the highest retatrutide dose lost an average of 25 percent of their body weight after 80 weeks, and an average of 30 percent after an extension period to 104 weeks. Overall, more than a third of participants taking retatrutide lost 30 percent or more of their weight.
The drug also proved effective at reducing knee pain (by up to 62 percent) in a subset of participants with obesity-linked knee osteoarthritis. It reduced the number of sleep apnea events per hour (by up to 57 percent) in a subset of participants with obesity-linked obstructive sleep apnea. The drug improved cardiometabolic measurements across the board, including blood pressure, triglycerides, and low-density lipoprotein cholesterol (bad cholesterol). At the start, more than a third of trial participants had prediabetes and, by the end, the condition had resolved in more than 90 percent of those participants.
The trial began in 2023 and included 2,339 participants from 131 clinical trial sites in 11 countries. Participants were broken into four nearly equal groups, given either: 4 mg of retatrutide, 9 mg, 12 mg, or a placebo. Across all groups, the average starting weight was around 113 kg (250 pounds), and the average body mass index (BMI) was 40. For the subset analyses, 574 participants had knee osteoarthritis, and 243 had obstructive sleep apnea. The results appeared today in the New England Journal of Medicine.
转载信息
评论 (0)
暂无评论，来留下第一条评论吧